SCHEMBL30430820

SCHEMBL30430820

COc1ccc(C(=O)N2CCC3(CC2)CN(CC=O)C3)cc1N1CCC(=O)NC1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 9/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ USP2 O75604 5/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ HIF1A Q16665 1/20 0.43
▸ CYP3A4 P08684 6/20 0.42
▸ TSHR P16473 3/20 0.41
▸ MLKL Q8NB16 1/20 0.40
▸ CRBN Q96SW2 1/20 0.40
▸ NR3C1 P04150 1/20 0.40
▸ PGR P06401 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ PDE3B Q13370 1/20 0.40
▸ PDE3A Q14432 1/20 0.40
▸ SOS1 Q07889 2/20 0.39
▸ TNKS O95271 1/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ PARP10 Q53GL7 1/20 0.39
▸ TNKS2 Q9H2K2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25211930 1.00 CYP2D6 (0.43) CYP2D6ALDH1A1USP2CYP1A2HIF1A
SCHEMBL29387309 0.94 CYP2D6 (0.45) CYP2D6USP2CYP1A2CYP3A4TSHR
SCHEMBL25217387 0.94 CYP2D6 (0.45) CYP2D6USP2CYP1A2CYP3A4TSHR
SCHEMBL30430021 0.93 CYP2D6 (0.39) CYP2D6ALDH1A1USP2CYP1A2HIF1A
SCHEMBL25249471 0.93 CYP2D6 (0.39) CYP2D6ALDH1A1USP2CYP1A2HIF1A
SCHEMBL25270082 0.90 NR3C1 (0.47) ALDH1A1TSHRNR3C1PGRSLC6A4
SCHEMBL30158156 0.90 NR3C1 (0.47) ALDH1A1TSHRNR3C1PGRSLC6A4
SCHEMBL25236749 0.87 CYP2D6 (0.44) CYP2D6USP2CYP1A2CYP3A4TSHR
SCHEMBL30267289 0.87 CYP2D6 (0.44) CYP2D6USP2CYP1A2CYP3A4TSHR
SCHEMBL25314195 0.85 CYP2D6 (0.42) CYP2D6USP2CYP3A4TSHRMLKL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2023-07-27 — — US disclosed
EP-4194457-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) 2023-06-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF IRAK4, IRAK2, IRAK1 CYP2D6 2818/4885ALDH1A1 3835/4885USP2 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback